What are the chances we presently have of carrying a cardiovascular disease at some point in our lives?

Original title: Lifetime Risk and Years Lived Free of Total Cardiovascular Disease Reference: John T. Wilkins et al. JAMA. 2012; 308(17):1795-1801.

This study analyzed more than 120,000 patients in the cohorts of large community studies, such as the Framingham, who did not have cardiovascular disease at the time of inclusion 

Considering all the age subgroups, only between 1.7% and 7.9% were within the optimal range of risk factors, (BP <120/80 mmHg, total cholesterol

In contrast, more than 55% of the population had one or two risk factors analyzed whatever their age. With this data it was possible to calculate, for example, that a 45 year-old man with no history has a 60.3% risk of contracting a cardiovascular disease at some point in his life.

For a woman of the same age the risk factor is 55.6%. In a middle age, a person with optimal risk control factors has an estimated 14 more years of free cardiovascular disease than someone of the same age with 2 risk factors. However, despite the likelihood of optimal control of risk, the odds of contracting an illness are still above 30%.

Editorial Comment: 

This study shows the enormous prevalence of cardiovascular disease and that this will continue to rise beyond the level that medical treatment can manage. Dealing with this huge number of patients is not only going to be a challenge for us in the catheterization laboratory but also an enormous public health problem.

SOLACI.ORG

More articles by this author

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Left Main Coronary Artery Disease: Intravascular Imaging-Guided PCI vs. Coronary Artery Bypass Grafting

Multiple randomized clinical trials have demonstrated superior outcomes with coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in patients with left main...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....